Clinical trial · Observational
Newer Therapeutic Targets in Head and Neck Cancers
A Cohort Study to Identify Newer Therapeutic Targets in Head and Neck Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes: 1. cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA); 2. cell-cycle control (e.g., CDKN2A and CCND1); 3. cellular differentiation (e.g., NOTCH1); and 4. Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways. Alterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head Neck Cancer | — | UNRESOLVED | — |
| Oral Cancer | Malignant Lip and Oral Cavity Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Next generation Sequencing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Head neck cancer
- description
- Histologically diagnosed cases of head and neck cancer
- interventionNames
- Other: Next generation Sequencing
Primary outcomes (2)
- measure
- Over all survival
- timeFrame
- 10 years
- description
- Survival time from the diagnosis to death
- measure
- Relapse free survival
- timeFrame
- 10 years
- description
- survival time from diagnosis to recurrence or metastasis
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven cases of primary head and neck cancers. Exclusion Criteria: * Patients under 18 years of age * Pregnant and lactating women * Multiple cancers or patients with cancer of other sites.
References
Publications (1)
- RESULTBatta N, Pandey M. Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance. World J Surg Oncol. 2019 Nov 27;17(1):198. doi: 10.1186/s12957-019-1741-2. PMID 31775759